Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.96 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.57 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2799201 | 1.00 | KMT2A (1.00) | KMT2AMEN1BLMPMP22MAOB | |
| SCHEMBL3506361 | 0.98 | MAOB (1.00) | KMT2AMEN1BLMPMP22MAOB | |
| SCHEMBL3861146 | 0.88 | MAOB (0.81) | KMT2AMEN1BLMPMP22MAOB | |
| SCHEMBL6859638 | 0.87 | CYP1A2 (0.80) | KMT2AMEN1BLMPMP22MAOB | |
| SCHEMBL9584535 | 0.86 | CYP1A2 (0.78) | KMT2AMEN1BLMPMP22MAOB | |
| SCHEMBL27956896 | 0.84 | CYP1A2 (0.75) | KMT2AMEN1BLMPMP22MAOB | |
| SCHEMBL7104101 | 0.84 | CYP1A2 (0.75) | KMT2AMEN1BLMPMP22MAOB | |
| Hydrochloric Acid SCHEMBL10614815 | 0.83 | BLM (0.71) | KMT2AMEN1BLMPMP22MAOB | |
| Hydrochloric Acid SCHEMBL32665514 | 0.83 | BLM (0.71) | KMT2AMEN1BLMPMP22MAOB | |
| SCHEMBL47366 | 0.82 | CYP1A2 (0.72) | KMT2AMEN1BLMPMP22MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635667-B2 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2003-10-21 | — | — | US | claimed |
| US-20020128299-A1 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2002-09-12 | — | — | US | claimed |
| US-6432991-B1 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2002-08-13 | — | — | US | claimed |
| EP-1052983-A2 | USE OF AN MAO-A OR MAO-B INHIBITOR FOR THE TREATMENT OF VASCULAR DISORDERS | Thomas, Thomas N. (US) | 2000-11-22 | — | — | EP | claimed |
| WO-1999037293-A2 | USE OF AN MAO-A OR MAO-B INHIBITOR FOR THE TREATMENT OF VASCULAR DISORDERS | THOMAS THOMAS N (US) | 1999-07-29 | — | — | WO | claimed |
| EP-3983068-B1 | NOVEL ARGINASE INHIBITORS | UNIV GRONINGEN (NL) | 2024-03-20 | — | — | EP | disclosed |
| US-11845767-B2 | Arginase inhibitors | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-12-19 | — | — | US | disclosed |
| US-20220227791-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-07-21 | — | — | US | disclosed |
| EP-3983068-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020249821-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-12-17 | — | — | WO | disclosed |
| US-8906894-B1 | Methods for preventing and treating thrombotic disorders | THOMAS THOMAS N (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| WO-1999021005-A2 | PHARMACEUTICAL GRADE ST. JOHN'S WORT | PHARMAPRINT, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0900375-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | Pharmaprint, Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5844003-A | Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function | INNOVATIONS FOUNDATION (CA) | 1998-12-01 | — | — | US | disclosed |
| US-5767164-A | Use of deprenyl to rescue damaged nerve cells | INNOVATIONS FOUNDATION (CA) | 1998-06-16 | — | — | US | disclosed |
| WO-1997039355-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | PHARMAPRINT, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997028791-A1 | USE OF DEPRENYL COMPOUNDS TO MAINTAIN, PREVENT LOSS, OR RECOVER NERVE CELL FUNCTION | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1997-08-14 | — | — | WO | disclosed |
| US-5444095-A | Use of deprenyl to rescue damaged nerve cells | UNIVERSITY OF TORONTO, INNOVATIONS FOUNDATION (CA) | 1995-08-22 | — | — | US | disclosed |
| US-5238962-A | Administering an antidepressants | HOFFMANN-LA ROCHE INC. (US) | 1993-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227791-A1 | NOVEL ARGINASE INHIBITORS | ARG1, ARG2, ARGLU1 | MAOB 303/4885GAA 659/4885HDAC3 850/4885 |
| US-11845767-B2 | Arginase inhibitors | ARG1, ARG2, ARGLU1 | MAOB 367/4885GAA 692/4885HDAC3 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.